Skip to main content

Advertisement

Table 1 Study characteristics of trials included in the analysis

From: The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma

Authors Treatment N Median PFS (months) Median Age (years) Median number of previous lines Mean baseline disease stageb Female (%)
RCT trials
 Chanan-Khan et al. [48] 1. ob7mg + dex40mg 110 3.09 62 3 2.6 46
2. dex40mg 114 3.55
 Chiou et al. [49] 1. thal100mg + IFN 16 1.5 63c 1 NR 14
2. thal100mg 12 7.9
 Dimopoulos et al. [50] 1.bor1.3 mg/m2 + vor400mg 317 7.63 62 2 1.9 41
2. bor1.3 mg/m2 320 6.83
 Dimopoulos et al. [51] 1. len25mg + dex40mg 176 11.3 63 NR 2.6 41
2. dex40mg 175 4.7
 Dimopoulos et al. [52] 1. carf20mg + dex20mg 464 18.7 65 2 1.8 51
2. bor1.3 mg/kg + dex20mg 465 9.4
 Hjorth et al. [53] 1. thal50mg + dex40mg 67 9 71 NR NR 47
2. bor1.3 mg/m2 + dex20mg 64 7.2
 Kropff et al. [54] 1. dex40mg 126 6 64 1–3 prior lines 1.9 57
2. thal100/200/400 mga 373 7.4
 Kropff et al. [55] 1. bor1.3 mg/kg + dex20mg 43 12.6 71 1 2.1 43d
2. bor1.3 mg/kg + dex20mg + cyc50mg 47 9.9
 Lonial et al. [56] 1. elo10mg/kg + len25mg + dex40mg 321 19.4 66 2 1.8 40.4d
2.len25mg + dex40mg 325 14.9
 Moreau et al. [57] 1. ixa4mg + len25mg + dex40mg 360 20.6 66 1 NR 43d
2. len25mg + dex40mg 363 14.7
 Orlowski et al. [58] 1. sil6mg + bor1.3 mg/m2 + dex40mg 142 8.1 62 1–3 prior lines NR NR
2. bor1.3 mg/m2 + dex40mg 144 7.6
 Orlowski et al. [59] 1. bor1.3 mg/m2 322 6.5 61 NR NR 44
2. PLD20mg + bor1.3 mg/m2 324 9
 Palumbo et al. [60] 1.elo10mg + bor1.3 mg/m2 + dex20mg 77 9.9 66 1d NR 48d
2. bor1.3 mg/m2 + dex20mg 75 6.8
 Richardson et al. [61] 1. pom4mg 108 2.7 63 5 2.6 46
2. pom4mg + dex40mg 113 4.2
 Nagler et al. [62] 1.peri50mg + bor1.3 mg/m2 + dex20mg 69 5.23 NR 1d NR 68
2. bor1.3 mg/m2 + dex20mg 66 8.29
 Richardson et al. [63] 1. bor1.3 mg/m2 333 6.22 61 2 NR 42
2. dex40mg 336 3.49
 San Miguel et al. [64] 1.pan20mg + bor1.3 mg/m2 + dex20mg 387 12 63 1 1.8 47
2. bor1.3 mg/m2 + dex20mg 381 8.1
 San Miguel et al. [14] 1. pom4mg + dex40mg 302 4 64 5 2 41
2. dex40mg 153 1.9
 Stewart et al. [65] [65] 1.carf20-17 mg + len25mg + dex40mg 396 26.3 64 2 NR 44
2. len25mg + dex40mg 396 17.6
 Weber et al. [66] 1. len25mg + dex40mg 177 11.1 63 1–3 prior lines 2.5 40
2. dex40mg 176 4.7
 White et al. [67] 1. bor1.3 mg/m2 53 5.1 65 1–3 prior lines 2.1 42
2. bor1.3 mg/m2 + bev400mg 49 6.2
 Hou et al. [68] 1. ixa + len + dex 57 6.7 NR 2 1.7 31
2. len + dex 58 4.0
 Dimopoulos et al. [69] 1. dara16mg/m2+ len25mg + dex40mg 286 54.1 65 1 1.7 NR
2. len25mg + dex40mg 283 18.4
 Garderet et al. [70] 1. bor1.3 mg/m2 + thal200mg + dex40mg 135 18.3 61 1 1.6 37
2. thal200mg + dex40mg 134 13.6
 Palumbo et al. [71] 1. dara 16 mg/m2 + bor1.3 mg/m2 + dex20 mg 251 18.5 64 2 1.8 43
2. bor1.3 mg/m2 + dex20 mg 247 7.2
Observational trials
 Avet-Loiseau et al. [40] dex40mg + len25mg 207 9.6 65 3 1.7 44
 Chang et al. [41] bor1.3 mg/m2 65 9.5 54 > = 2 1.3 31
 Fukushima et al. [72] bor1.3 mg/m2 + dex20mg 22 16.8 69 2 2.1 41
 Hou et al. [73] dex20/40 mg + len25mg 199 8.3 60 4 2.8 47
 Kneppers et al. [42] dex40mg + len25mg 117 10 61 3.5 2.7 37
 Lacy et al. [74] dex40mg + pom2mg 34 4.8 62 4 1.7 32
 Moore et al. [43] bor1.3 mg/m2 52 13 72 1 2.6 40
 Oehrlein et al. [75] Dex < 160-480 mg 26 11.6 71 2 2.8 54
Len10-25 mg
 Pantani et al. [76] bor1.3 mg/m2 + dex20mg 85 8.7 58 2 2.4 40
 Richardson et al. [77] bor1.3 mg/m2 + dex40mg + pan20mg 55 5.4 61 4 1.9 47
 Terpos et al. [78] dex40mg + thal200mg 35 8 63 2 2.2 34
 Walter-Croneck et al. [44] bor1.3 mg/m2 708 14 60 1 2.1 55
  1. bev bevacizumab, bor bortezomib, carf carfilzomib, cyc cyclophosphamide, dara daratumumab, dex dexamethasone, elo elozumatab, IFN interferon alpha, ixa ixazomib, len lenalidomide, ob oblimersen, pan panobinostat, peri perifosine, PLD pegylated liposomal doxorubicin, pom pomalidomide, sil silituximab, thal thalidomide, vor vorinostat
  2. aPooled results from 3 arms investigating different doses
  3. bestimated excluding patients with unknown baseline stage
  4. cprobably not median but does not state exact method (presumably mean and SD)
  5. dmedian